Menu
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Buy Currently
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Sample Portfolio
Sample Portfolio Analysis
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Account Requirements
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
Municipal Bond Presentation
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Normally Buy
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF® Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Vertex Pharmaceuticals
(NQ:
VRTX
)
547.55
+0.26 (+0.05%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 27, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Vertex Pharmaceuticals
< Previous
1
2
...
21
22
23
24
25
26
27
28
29
...
76
77
Next >
What Analysts Are Saying About Vertex Pharmaceuticals Stock
↗
October 01, 2024
Via
Benzinga
Pfizer Tanked A $5.4 Billion Takeover. Why Crispr, Agios, Beam Could Benefit.
↗
September 26, 2024
Pfizer stock dipped Thursday after the company voluntarily pulled its sickle cell drug, Oxbryta, from the market following patient deaths.
Via
Investor's Business Daily
Vertex Highlights First Oral Presentation of Phase 3 Clinical Data of the Vanza Triple and New Data on Long-Term Impact of TRIKAFTA® at the North American Cystic Fibrosis Conference
September 26, 2024
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
If You Invested $100 In This Stock 15 Years Ago, You Would Have $1,200 Today
↗
September 25, 2024
Via
Benzinga
Demystifying Vertex Pharmaceuticals: Insights From 16 Analyst Reviews
↗
September 19, 2024
Via
Benzinga
Looking Into Vertex Pharmaceuticals's Recent Short Interest
↗
September 18, 2024
Via
Benzinga
Vertex Pharmaceuticals's Options Frenzy: What You Need to Know
↗
August 29, 2024
Via
Benzinga
The Best Biotech Stock to Invest $1,000 in Right Now
↗
September 22, 2024
Vertex Pharmaceuticals isn't an ordinary biotech stock.
Via
The Motley Fool
Bull Market and Beyond: 2 Stocks Just Waiting to Soar
↗
September 21, 2024
Great companies have persisted even in a tumultuous market.
Via
The Motley Fool
Prediction: These Could Be the Best-Performing Biotech Stocks Through 2030
↗
September 18, 2024
These biotech stocks have what it takes to be the biggest winners through the rest of the decade and beyond.
Via
The Motley Fool
3 Stocks to Buy and Hold Forever
↗
September 14, 2024
These stocks are built for the long run.
Via
The Motley Fool
Prediction: These 3 Phenomenal Stocks Are Set to Soar
↗
September 14, 2024
These stocks are already solid winners in 2024. They should be able to keep the momentum going.
Via
The Motley Fool
Time To Invest And Or Trade In Bio-Tech Stocks?
↗
September 13, 2024
Biotechnology stocks and biotech exchange-traded funds ETFs once played a significant role in growth equity rallies, but today it seems like those days are in the past. Will an interest rate cut help...
Via
Talk Markets
Topics
ETFs
Looking Into Vertex Pharmaceuticals's Recent Short Interest
↗
August 27, 2024
Via
Benzinga
Unpacking the Latest Options Trading Trends in Vertex Pharmaceuticals
↗
August 23, 2024
Via
Benzinga
Biotech Breakout: Stocks for Your Watchlist
September 12, 2024
The iShares Biotechnology ETF (IBB) has turned $140 resistance into support, positioning the overall sector for a potential breakout above $150.
Via
MarketBeat
Topics
ETFs
Here's How Much You Would Have Made Owning Vertex Pharmaceuticals Stock In The Last 20 Years
↗
September 06, 2024
Via
Benzinga
3 No-Brainer Stocks to Buy in September
↗
August 31, 2024
There's at least one key common denominator here: tremendous growth prospects.
Via
The Motley Fool
3 Rock-Solid Pharma Stocks to Buy Now and Hold Forever
↗
August 30, 2024
These three have secure core businesses, plus multiple paths to grow.
Via
The Motley Fool
3 Reasons to Buy Vertex Pharmaceuticals Stock Like There's No Tomorrow
↗
August 30, 2024
Vertex should have a future full of bright tomorrows.
Via
The Motley Fool
If You Invested $100 In This Stock 20 Years Ago, You Would Have $4,900 Today
↗
August 21, 2024
Via
Benzinga
Biotech And Life Science Sector Update Summer Of 2024
↗
August 29, 2024
It’s the slowest week of the year, we are at the market top and most earnings reports are good.
Via
Talk Markets
Jim Cramer: 'Hold On' To Builders FirstSource, 'Here's The Problem' With Viking Therapeutics
↗
August 29, 2024
Jim Cramer discusses Serve Robotics, Builders FirstSource, Vertex Pharmaceuticals and Viking Therapeutics on CNBC.
Via
Benzinga
Forget Novo Nordisk: Buy This Magnificent Pharma Stock Instead
↗
August 23, 2024
Vertex Pharmaceuticals has a lot going for it.
Via
The Motley Fool
Vertex to Participate in Upcoming September Investor Conferences
August 22, 2024
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
Biotech Bull Market: 3 Ways To Play It
↗
August 20, 2024
Although we are in the later stages of this bull market a cut in interest rates by the Fed should help biotech as you have seen from the recent rally.
Via
Talk Markets
Topics
Economy
Soviet Code Breaker Jim Simons' Hedge Fund Renaissance Technologies — Ozempic, Wegovy Maker Novo Nordisk Along With Nvidia, Palantir Among Top Holdings
↗
August 19, 2024
Renaissance Technologies, the hedge fund founded by legendary mathematician and former NSA code breaker Jim Simons, recently disclosed its latest stock holdings in a 13F filing with the U.S. Securities...
Via
Benzinga
These 2 Incredible Growth Stocks Are Set to Soar This Summer and Beyond
↗
August 18, 2024
It's always a good time to invest cash in quality businesses.
Via
The Motley Fool
3 Fantastic Growth Stocks to Buy in August
↗
August 17, 2024
These stocks should keep up their winning ways.
Via
The Motley Fool
10 Health Care Stocks With Whale Alerts In Today's Session
↗
August 15, 2024
Via
Benzinga
< Previous
1
2
...
21
22
23
24
25
26
27
28
29
...
76
77
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.